The cancer treatment developer is set to go public in an offering which would represent exits for Pfizer Ventures, Leaps by Bayer and Ipsen.
Pyxis Oncology, the US-based immuno-oncology treatment developer backed by pharmaceutical firms Bayer, Pfizer and Ipsen, has filed for an initial public offering on the Nasdaq Global market.
Founded in 2018, Pyxis is developing drugs to target difficult-to-treat forms of cancer, harnessing the immune system to kill tumours. It has a development pipeline of monoclonal antibodies and antibody drug conjugates, and three potential treatments are in Investigational New Drug-enabling studies.
The company has set a placeholder target of $100m for…
Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
